Phase 3, 12-week, multicenter, double-blind, randomized, efficacy and safety study of lubiprostone for the treatment of irritable bowel syndrome with constipation

Trial Profile

Phase 3, 12-week, multicenter, double-blind, randomized, efficacy and safety study of lubiprostone for the treatment of irritable bowel syndrome with constipation

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Lubiprostone (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Sucampo Pharmaceuticals
  • Most Recent Events

    • 28 Aug 2017 Results of post-hoc pooled analysis of this and other 5 studies published in the Digestive Diseases and Sciences.
    • 27 Sep 2016 Results of post-hoc pooled analysis (n=505) of this and one other phase III study published in the Alimentary Pharmacology and Therapeutics (2016).
    • 01 Feb 2009 Results published in Alimentary Pharmacology and Therapeutics, according to 1136688.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top